Smartlab Europe

Clinical Trials

Merck, Junshi Biosciences collaborate to explore head, neck cancer treatment

Junshi Biosciences , a China-based biopharmaceutical company specializing in discovery, development and commercialization of novel therapies, and Merck, a world leading science and technology company, announced their collaboration on a clinical trial program designed to investigate the efficacy and...

Lilly Begins World’s First Study of a Potential COVID-19 Antibody Treatment in Humans

Eli Lilly and Company announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19. This investigational medicine, referred to as LY-CoV555, is the first to emerge from the collaboration between Lilly...

LabCorp Accelerates Adoption of Decentralized Clinical Trials, Expands Technology Ecosystem Through Alliance With Medable

LabCorp, a leading global life sciences company that is deeply integrated in guiding patient care, announced that Covance, its drug development business, is expanding its technology ecosystem to accelerate the adoption of decentralized clinical trials, often referred to as...

Roche’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration

Roche announced positive topline results from the phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or “wet” age-related macular degeneration (nAMD). PDS is a permanent refillable eye implant, approximately the size...

Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine

Novavax, Inc. , a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVX CoV2373, a stable, prefusion protein made using...

Glenmark to Combine Two Anti-Viral Drugs; Start Trials on Indian COVID-19 Patients

Glenmark Pharmaceuticals announced on Tuesday that it will commence another new Phase 3 clinical trial on a combination of two anti-viral drugs Favipiravir and Umifenovir in hospitalized patients of moderate COVID-19 in India. Glenmark has received approval from the...

AstraZeneca collaborates with ArcherDX to use personalised cancer assays to detect minimal residual disease in lung cancer trials

AstraZeneca will collaborate with ArcherDX, a genomic analysis company focused on precision oncology, to use personalised cancer monitoring to detect minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer (NSCLC). ArcherDX’s personalised assay will be used in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »